Shots:Shots: The Phase 1/2 study assesses the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion of […]readmore
Tags : BNT162
Shots: The companies reported that the first cohort of BioNTech’s P-I/II clinical trial has dosed 12 participants with BNT162 in Germany since dosing began on Apr 23, 2020. Following the […]readmore
Shots: The companies collaborate to accelerate the development of BioNTech’s BNT162, which is anticipated to enter clinical studies by the end of Apr’2020. The alliance will leverage the expertise and […]readmore
Shots: BioNTech to receive $135M as up front, future investment & milestone payments and $50M as an equity investment for 1,580,777 ordinary shares in BioNTech. Fosun to get the rights […]readmore